Addendum
Cabozantinib (renal cell carcinoma) - Addendum to Commission A21-49
Report documents
-
Addendum
Cabozantinib (renal cell carcinoma) - Addendum to Commission A21-49
Dossier assessment
Indication:
Adult patients with treatment-naive advanced renal cell carcinoma
Result of dossier assessment:
Unchanged after addendum:
- Adults with favourable risk profile (IMDC score 0): added benefit not proven.
- Adults with intermediate (IMDC score 1-2) or unfavourable risk profile (IMDC score ≥ 3): added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2021-10-21 A G-BA decision was published.
Project details
- Project no.
- A21-119
- Commission
- Commission awarded on 08.09.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed